Adding to the ever-growing list of newly discovered bacterial immune systems, we have characterized the mechanisms of an ...

Choosing a film for a movie night is always a battle. Now imagine if you could pick one that provided a window into some of ...

ArrakisTx was formed to create RNA-intercepting drugs to fight cancer. Despite some promising data, CEO @michael_gilman says it will shift targets.

By deducing the possible ancient forms of a bacterial enzyme, OIST scientists have resurrected one of its ancestral versions, ...

Pharma giant GSK is buying into Rgenta Therapeutics’ mission to develop a pipeline of oral RNA-targeting small molecules. | ...

"Dune"-inspired Arrakis Therapeutics has tested its spice—an RNA-targeting small molecule—in a mouse model of myotonic ...

4′-Fluorouridine works against RNA-dependent RNA polymerase, an enzyme that helps viruses assemble RNA. The compound has a ...

Rgenta Therapeutics, a clinical-stage biotechnology company pioneering the development of a new class of oral small molecules ...

The United States Food and Drug Administration has just approved the first-ever clinical trial that uses CRISPR-Cas13 RNA ...

Dominique Verhelle is co-founder and CEO of the Brighton-based company NextRNA Therapeutics, which uses long non-coding RNA ...

Researchers investigate the influence of Mettl1 on energy metabolism and the maturation of heart cells after birth.

This study provides a valuable look at genome-wide RNaseA-resistant RNA-DNA interactions in human embryonic stem cells. The research indicated that RNase treatment maintained long-range RNA-chromatin ...